<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119738">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544114</url>
  </required_header>
  <id_info>
    <org_study_id>D1120C00037</org_study_id>
    <nct_id>NCT01544114</nct_id>
  </id_info>
  <brief_title>A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)</brief_title>
  <official_title>A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Pharma Ireland, Ltd., Dublin Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 6 month study of VIMOVO in adolescents aged 12-16 years with juvenile idiopathic Arthritis
      (JIA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and
      500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, with
      Juvenile Idiopathic Arthritis (JIA)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).</measure>
    <time_frame>For AEs: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, and Month 6.5. For SAEs: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, and Month 6.5.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum iron/total iron binding capacity (serum iron/TIBC), Vitamin B12, and magnesium.</measure>
    <time_frame>Will be assessed at baseline and Month 6 or at the early termination (ET) visit.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs, physical examination results, and clinical laboratory tests.</measure>
    <time_frame>Baseline, Month 1, Month 3, and Month 6.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) in terms of characteristics of VIMOVO (naproxen / esomeprazole).</measure>
    <time_frame>Sparse PK sampling: Months 1 and 3. Frequent PK sampling: Month 1 only.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Juvenile Idiopathic Arthritis (JIA)</condition>
  <arm_group>
    <arm_group_label>VIMOVO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIMOVO (naproxen/esomeprazole) tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIMOVO 250/20</intervention_name>
    <description>250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months</description>
    <arm_group_label>VIMOVO</arm_group_label>
    <other_name>250 mg naproxen/20 mg esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIMOVO 375/20</intervention_name>
    <description>375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months</description>
    <arm_group_label>VIMOVO</arm_group_label>
    <other_name>375 mg naproxen/20 mg esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIMOVO 500/20</intervention_name>
    <description>500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months</description>
    <arm_group_label>VIMOVO</arm_group_label>
    <other_name>500 mg naproxen/20 mg esomeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent or legal guardian is able to provide written informed consent and patient is
             able to provide written assent if appropriate.

          -  Male and female adolescents aged 12 to 16 years at the time of enrollment.

          -  Diagnosed with JIA, including all the ILAR JIA subtypes: oligoarthritis,
             polyarthritis (both RF+ and RF-), psoriatic arthritis, enthesitis-related
             arthritis,undifferentiated arthritis, and systemic arthritis.

          -  Based upon investigator judgment, it is determined appropriate for the patient to
             undergo 6 months of continuous treatment with VIMOVO.

          -  Body weight &gt;31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass
             index for age.

        Exclusion Criteria:

          -  In systemic JIA patients, presence of systemic features (ie, fever, rheumatoid rash,
             serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to
             start of study drug.

          -  Currently taking (ie, within 4 weeks prior to start of drug) naproxen &gt;20 mg/kg/day
             or &gt;1000 mg total daily dose.

          -  Hemoglobin â‰¤8.5 g/dL.

          -  Individuals who have cardiovascular or cerebrovascular disease, based on history or
             risk factors.

          -  Any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other
             medical conditions indicated by medical/surgical history, physical, or laboratory
             examination that might put the patient at greater risk during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lovell, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 11, 2016</lastchanged_date>
  <firstreceived_date>February 21, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>February 11, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
